Today, a Major Shareholder at Ardelyx (ARDX), Scott Sandell, sold shares of ARDX for $1,764.
This is Sandell’s first Sell trade following 3 Buy transactions.
See today’s analyst top recommended stocks >>
Based on Ardelyx’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $172K and GAAP net loss of $24.13 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $20.72 million. Currently, Ardelyx has an average volume of 591.3K.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicine for the treatment of renal diseases. It also focuses on the development of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations.
